Nifty 17053.95 (0.16%)
Sensex 57260.58 (0.27%)
Nifty Bank 35976.45 (-0.14%)
Nifty IT 34870.75 (0.76%)
Nifty Financial Services 17629.95 (0.09%)
Adani Ports 702.60 (-2.03%)
Asian Paints 3144.30 (0.04%)
Axis Bank 651.10 (-1.61%)
B P C L 367.45 (-2.49%)
Bajaj Auto 3298.20 (-1.09%)
Bajaj Finance 6905.75 (1.45%)
Bajaj Finserv 16890.40 (1.25%)
Bharti Airtel 739.35 (0.08%)
Britannia Inds. 3528.60 (-0.75%)
Cipla 965.00 (-0.18%)
Coal India 154.25 (-1.06%)
Divis Lab. 4921.35 (-0.33%)
Dr Reddys Labs 4697.60 (-1.12%)
Eicher Motors 2413.40 (-0.84%)
Grasim Inds 1683.95 (-0.36%)
H D F C 2713.80 (-1.02%)
HCL Technologies 1133.15 (2.08%)
HDFC Bank 1501.25 (0.76%)
HDFC Life Insur. 683.65 (1.94%)
Hero Motocorp 2490.80 (-1.53%)
Hind. Unilever 2329.40 (-0.24%)
Hindalco Inds. 420.15 (0.76%)
I O C L 118.80 (-1.78%)
ICICI Bank 718.40 (-0.53%)
IndusInd Bank 895.45 (-0.70%)
Infosys 1696.35 (0.28%)
ITC 221.50 (-1.12%)
JSW Steel 625.60 (-0.49%)
Kotak Mah. Bank 2019.60 (2.82%)
Larsen & Toubro 1767.25 (-0.61%)
M & M 850.80 (-0.35%)
Maruti Suzuki 7149.50 (-0.29%)
Nestle India 19000.40 (-1.15%)
NTPC 126.50 (-1.82%)
O N G C 144.10 (-2.04%)
Power Grid Corpn 200.25 (-0.87%)
Reliance Industr 2441.50 (1.20%)
SBI Life Insuran 1136.25 (0.52%)
Shree Cement 25540.05 (-1.56%)
St Bk of India 465.10 (-1.15%)
Sun Pharma.Inds. 751.05 (-2.12%)
Tata Consumer 766.00 (-0.09%)
Tata Motors 461.45 (0.27%)
Tata Steel 1114.75 (0.22%)
TCS 3502.00 (1.60%)
Tech Mahindra 1536.65 (0.61%)
Titan Company 2324.20 (1.39%)
UltraTech Cem. 7388.25 (-0.09%)
UPL 689.35 (-2.05%)
Wipro 630.60 (1.47%)
INFY

Gland Pharma Ltd.

₹3607.5
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Gland Pharma

  • Master Rating:
  • Gland Pharma has an operating revenue of Rs. 3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 7% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 91 which is a GREAT score indicating consistency in earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 144 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Gland Pharma Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Gland Pharma Ltd Synopsis

NSE-Medical-Generic Drugs

Gland Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 3462.88 Cr. and Equity Capital is Rs. 16.36 Cr. for the Year ended 31/03/2021. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is U24239TG1978PLC002276 and registration number is 002276.
  • Market Cap

    INR 59,271.95 Cr

  • Sales

    INR 3,981.54 Cr

  • Shares in Float

    6.90 Cr

  • No of Funds

    189 K

  • Yield

    %

  • Book Value

    10

  • U/D Vol Ratio

    1.1

  • LTDebt/Equity

    0%

  • Alpha

    0.2

  • Beta

    0.18

Gland Pharma Ltd Ownership
Gland Pharma Ltd Management

Gland Pharma Ltd Financials

INDICATORMar 2021Mar 2020
Total ShareHolders Funds Annual Cr 5903.2853646.235
Fixed Assets Annual Cr 1292.0381156.566
Total Non Current Assets Annual Cr 1372.9891239.749
Total Current Assets Annual Cr 5123.0662846.29
Total Assets Annual Cr 6496.0554086.039
INDICATORMar 2021Mar 2020
Book Value Per Share Annual Rs 360.8585235.3168
ROE Annual % 16.8821.19
ROCE Annual % 22.3626.83
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 41.4941.56

Gland Pharma Ltd Technicals

EMA & SMA

CURRENT PRICE

3607.5 (2.93)

    • Bullish Moving Averages 13
    • Bearish Moving Averages 3

EMA

  • 20 Day

    3574.78

  • 50 Day

    3658.72

  • 100 Day

    3603.42

  • 200 Day

    3274.36

Gland Pharma Ltd Resistance and support

3518.69 PIVOT

  • First Resistance

    3561.17

  • Second Resistance

    3617.49

  • Third Resistance

    3659.97

  • First Support

    3462.37

  • Second Support

    3419.89

  • Third Support

    3363.57

  • RSI

    50.44

  • MFI

    61.25

  • MACD

    -48.3

  • MACD signal line

    -59.05

Gland Pharma Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 609,970 45,540,360 74.66%
Week 278,761 20,525,187 73.63%
1 Month 187,507 12,722,321 67.85%
6 Month 263,609 15,181,265 57.59%

Gland Pharma Ltd Price change analysis

-86

Over 1 month

Low High
3355 3779.9

-322.75

Over 3 month

Low High
3312.15 4179.65

389.1

Over 6 months

Low High
3009 4350

1494.5

Over Year

Low High
2050 4350

Similar Stocks

News

Gland Pharma Ltd - 543245 - Announcement under Regulation 30

Schedule of Meetings Read More

Gland Pharma Ltd - 543245 - Announcement under Regulation 30

Schedule of Investor Meetings Read More

Gland Pharma Ltd - 543245 - Announcement under Regulation 30

Meeting with Pictet Asset Management UK Ltd. Read More

Gland Pharma Ltd - 543245 - Announcement under Regulation 30

Meeting with Pictet Asset Management UK Ltd. Read More

Gland Pharma Ltd - 543245 - Announcement under Regulation 30

Schedule of Investor meetings Read More

Blogs

FAQs